<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01950468</url>
  </required_header>
  <id_info>
    <org_study_id>NAV5-02</org_study_id>
    <nct_id>NCT01950468</nct_id>
  </id_info>
  <brief_title>A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes</brief_title>
  <official_title>Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navidea Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navidea Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, open-label, multiple-center, randomized cross-over study to assess the&#xD;
      safety and efficacy of [123I]NAV5001 SPECT imaging in aiding in the differentiaion of&#xD;
      parkinsonian syndromes from non-parkinsonian tremor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The entire drug development program for this molecule was sold to another company.&#xD;
  </why_stopped>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of Parkinson' Syndrome based on the Movement Disorder Specialist Consensus Panel</measure>
    <time_frame>One Year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of positve [123I]NAV5001 SPECT brain scans</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of Parkinson' Syndrome based on the on-site neurologist assessment</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of Parkinson' Syndrome based on the on-site neurologist assessment at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of Parkinson' Syndrome based on the on-site neurologist assessment at 1 year</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events post baseline</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The incidence of positve DaTscan SPECT brain scans</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Parkinson's Syndrome</condition>
  <arm_group>
    <arm_group_label>NAV5001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DaTscan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NAV5001</intervention_name>
    <description>A single intravenous dose of 8.0 ± 1.0 mCi</description>
    <arm_group_label>NAV5001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DaTscan</intervention_name>
    <description>A single intravenous dose of 3 to 5 mCi</description>
    <arm_group_label>DaTscan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has provided written informed consent before the initiation of any study&#xD;
             related procedures and continues to give willing consent for participation&#xD;
&#xD;
          -  Age ≥ 40 years&#xD;
&#xD;
          -  Have had upper extremity tremor for &lt; 3 years duration, regardless of presumed&#xD;
             diagnosis or etiology&#xD;
&#xD;
          -  Have a UPDRS part III score upon entry of ≤ 16&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically significant or unstable physical or psychological illness based on&#xD;
             medical history or physical examination at screening, as determined by the&#xD;
             investigator&#xD;
&#xD;
          -  Structural brain abnormality affecting the entire brain (e.g., normal pressure&#xD;
             hydrocephalus) or the striatum (e.g., local tumor or stroke)&#xD;
&#xD;
          -  Any clinically significant abnormal laboratory results obtained at screening and as&#xD;
             determined by the investigator&#xD;
&#xD;
          -  Any clinically significant abnormal electrocardiogram (ECG) results obtained at&#xD;
             screening and as determined by the investigator&#xD;
&#xD;
          -  Any history of drug, narcotic, or alcohol abuse within 2 years before the date of&#xD;
             informed consent, as defined by the Diagnostic and Statistical Manual of the American&#xD;
             Psychiatric Association, Fourth Edition, revised (DSM-IV-TR [American Psychiatric&#xD;
             Association, 1994])&#xD;
&#xD;
          -  Positive urine drug screen for opiates, cocaine, or amphetamines at screening&#xD;
&#xD;
          -  Positive pregnancy test before imaging&#xD;
&#xD;
          -  Participation in an investigational drug or device clinical trial within 30 days&#xD;
             before the date of informed consent&#xD;
&#xD;
          -  Previous scan with any DAT imaging agent (e.g. [123I]NAV5001, Altropane, DaTscan,&#xD;
             DOPASCAN)&#xD;
&#xD;
          -  Any exposure to radiopharmaceuticals within 30 days before the date of informed&#xD;
             consent&#xD;
&#xD;
          -  Breast-feeding&#xD;
&#xD;
          -  Inability to lie supine for 1 hour&#xD;
&#xD;
          -  Any thyroid disease other than adequately treated hypothyroidism&#xD;
&#xD;
          -  Known sensitivity or allergy to iodine or iodine containing products&#xD;
&#xD;
          -  Treatment within the 30 days before the date of imaging with amoxapine, amphetamine,&#xD;
             benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine,&#xD;
             methylphenidate, norephedrine, phentermine, phenylpropanolamine, selegiline, and&#xD;
             sertraline, paroxetine, or citalopram.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelia Reininger, M.D. Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Navidea Biopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xenoscience, Inc.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>September 23, 2013</study_first_submitted>
  <study_first_submitted_qc>September 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2013</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

